Infection: COVID -19阳性患者的相关凝血因子和多种止血标志物都会存在异常

2022-10-14 xuyihan MedSci原创

COVID-19一般指新型冠状病毒肺炎。 新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19),简称“新冠肺炎”,世界卫生组织命名为“2019冠状病毒病”。

凝血功能障碍仍然是一种严重的、尚未被充分理解的COVID -19患者的并发症。它的形式和严重程度可以决定患者的治疗方案及其结果。虽然D-二聚体已被证明可以反映 COVID-19 患者的严重程度和预后,但凝血酶原时间 (PT)、国际标准化比值 (INR)、部分促凝血酶原激酶时间 (APTT) 和纤维蛋白原的作用尚不明确。免疫血栓相关 COVID-19 感染被认为与 COVID 相关凝血病 (CAC) 的发病机制相关。由于内皮细胞损伤是COVID-19发病机制中的一个恒定特征,血管性血友病因子 (VWF) 和因子 VIII (FVIII) 过量、释放和升高程度可能是一个很好的诊断和预后标志物疾病。本项研究旨在评估患有COVID-19的患者相关凝血病和多种止血标志物。此外,评估凝血急性期反应物及其对结果的影响。

 

 

 

该研究包括106名COVID-19患者和 51名对照患者。所有患者的鼻咽拭子检测COVID-19 感染均呈阳性。除了基线数据和放射学检查结果外,凝血曲线还特别关注纤维蛋白原、D-二聚体、因子 VIII、血管性血友病因子 (VWF)、蛋白 C、蛋白 S、抗凝血酶 III (ATIII) 和狼疮抗凝剂 (LA )-1 和 2的水平差异。

 

 

 

研究结果显示COVID-19阳性患者的VWF、D-二聚体和 LA1和 LA2显着高于对照组。在严重COVID-19症状患者组中检测到显着更高的D-二聚体 FVIII、VWF 和 LA1-2。ATIII ,而且有很高的诊断准确性。同时,研究人员发现血栓事件患者的国际随机比率 (INR) 和 VWF 显着升高。

 

 

 

本项研究证实感染COVID-19病毒的患者易患不同形式的凝血病。这可能与不良结果有关。D-二聚体是诊断、严重程度评估而非血栓形成预测的主要工具。早期筛查这种并发症及其适当的管理将改善预后。

 

 

 

 

原始出处:

Azza Abdelaal. et al. Assessment of COVID -19 associated coagulopathy and multiple hemostatic markers: a single center study in Egypt. Infection.2022.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2095487, encodeId=264e209548ee5, content=``丶1′家学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnHtEgiaNiaUeanPblicnQPORicamAtCLvWmTKDxxWwF3J99R5MdjnGACh16icoScCeRrNQOibvvPqiaDrA/132, createdBy=83465314460, createdName=八骏奔腾, createdTime=Sun Oct 23 09:11:37 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093888, encodeId=ea33209388846, content=讲的很详细,学习懂了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221015/7e7192f7e99647068d90397a1bff0b91/12e917b1a9cf4cdb963692433a16aebd.jpg, createdBy=7a2c8377794, createdName=孙羲和, createdTime=Sat Oct 15 09:26:43 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093868, encodeId=7b06209386874, content=不错学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Oct 15 06:02:01 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093854, encodeId=8927209385485, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Fri Oct 14 23:05:32 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093853, encodeId=f08220938535a, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Fri Oct 14 23:05:24 CST 2022, time=2022-10-14, status=1, ipAttribution=)]
    2022-10-23 八骏奔腾

    ``丶1′家学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2095487, encodeId=264e209548ee5, content=``丶1′家学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnHtEgiaNiaUeanPblicnQPORicamAtCLvWmTKDxxWwF3J99R5MdjnGACh16icoScCeRrNQOibvvPqiaDrA/132, createdBy=83465314460, createdName=八骏奔腾, createdTime=Sun Oct 23 09:11:37 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093888, encodeId=ea33209388846, content=讲的很详细,学习懂了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221015/7e7192f7e99647068d90397a1bff0b91/12e917b1a9cf4cdb963692433a16aebd.jpg, createdBy=7a2c8377794, createdName=孙羲和, createdTime=Sat Oct 15 09:26:43 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093868, encodeId=7b06209386874, content=不错学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Oct 15 06:02:01 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093854, encodeId=8927209385485, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Fri Oct 14 23:05:32 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093853, encodeId=f08220938535a, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Fri Oct 14 23:05:24 CST 2022, time=2022-10-14, status=1, ipAttribution=)]
    2022-10-15 孙羲和

    讲的很详细,学习懂了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2095487, encodeId=264e209548ee5, content=``丶1′家学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnHtEgiaNiaUeanPblicnQPORicamAtCLvWmTKDxxWwF3J99R5MdjnGACh16icoScCeRrNQOibvvPqiaDrA/132, createdBy=83465314460, createdName=八骏奔腾, createdTime=Sun Oct 23 09:11:37 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093888, encodeId=ea33209388846, content=讲的很详细,学习懂了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221015/7e7192f7e99647068d90397a1bff0b91/12e917b1a9cf4cdb963692433a16aebd.jpg, createdBy=7a2c8377794, createdName=孙羲和, createdTime=Sat Oct 15 09:26:43 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093868, encodeId=7b06209386874, content=不错学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Oct 15 06:02:01 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093854, encodeId=8927209385485, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Fri Oct 14 23:05:32 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093853, encodeId=f08220938535a, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Fri Oct 14 23:05:24 CST 2022, time=2022-10-14, status=1, ipAttribution=)]
    2022-10-15 仁术2021

    不错学习了。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2095487, encodeId=264e209548ee5, content=``丶1′家学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnHtEgiaNiaUeanPblicnQPORicamAtCLvWmTKDxxWwF3J99R5MdjnGACh16icoScCeRrNQOibvvPqiaDrA/132, createdBy=83465314460, createdName=八骏奔腾, createdTime=Sun Oct 23 09:11:37 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093888, encodeId=ea33209388846, content=讲的很详细,学习懂了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221015/7e7192f7e99647068d90397a1bff0b91/12e917b1a9cf4cdb963692433a16aebd.jpg, createdBy=7a2c8377794, createdName=孙羲和, createdTime=Sat Oct 15 09:26:43 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093868, encodeId=7b06209386874, content=不错学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Oct 15 06:02:01 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093854, encodeId=8927209385485, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Fri Oct 14 23:05:32 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093853, encodeId=f08220938535a, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Fri Oct 14 23:05:24 CST 2022, time=2022-10-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2095487, encodeId=264e209548ee5, content=``丶1′家学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnHtEgiaNiaUeanPblicnQPORicamAtCLvWmTKDxxWwF3J99R5MdjnGACh16icoScCeRrNQOibvvPqiaDrA/132, createdBy=83465314460, createdName=八骏奔腾, createdTime=Sun Oct 23 09:11:37 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093888, encodeId=ea33209388846, content=讲的很详细,学习懂了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221015/7e7192f7e99647068d90397a1bff0b91/12e917b1a9cf4cdb963692433a16aebd.jpg, createdBy=7a2c8377794, createdName=孙羲和, createdTime=Sat Oct 15 09:26:43 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093868, encodeId=7b06209386874, content=不错学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sat Oct 15 06:02:01 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093854, encodeId=8927209385485, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Fri Oct 14 23:05:32 CST 2022, time=2022-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093853, encodeId=f08220938535a, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Fri Oct 14 23:05:24 CST 2022, time=2022-10-14, status=1, ipAttribution=)]
    2022-10-14 ms6000000960504356

    不错的文章

    0

相关资讯

BJH:托珠单抗和秋水仙碱在新型冠状病毒肺炎相关凝血中的冲突影响

TCZ在covid-19患者的好处可能是由于发现抗体只能部分抑制IL-6介导的炎症活动(7)和未能阻止α-Def的释放和随后增加d二聚体代表的凝血加速。

血栓弹力图,“弹”的是什么?

在门诊时经常会有病人拿着血栓弹力图的化验报告过来咨询,“大夫,我得没得血栓啊?严不严重啊?”普罗大众对于血栓弹力图的认知都是从字面意思来理解,今天我们就来谈谈血栓弹力图到底&l

HCT极高导致的凝血结果异常应该怎么处理?

凝血功能检测作为术前检查必做项目,在辅助诊断出血性疾病、血栓性疾病中具有重要作用,同时也是监测抗凝治疗的重要指标。

患儿突发凝血异常,究竟是什么原因呢?

患者,男,7岁,于入院2天前无明显诱因出现双侧鼻出血,偶尔量大,自行卫生纸填塞,鼻出血可止住,反复间断发作,因入院当日早晨再发鼻出血,头晕、乏力,伴呕吐血性分泌物,就诊于我院,门诊以“鼻出血”收入院。

凝血或是导致长期症状的根本原因,SARS康复者接种疫苗后产生更高水平抗体:新冠研究一周进展

近日,发表于《血栓与止血杂志》(Journal of Thrombosis and Haemostasis)的一项研究表明,凝血可能是导致一些新冠肺炎患者在感染消失后出现持续数周或数月“长期症状”的根

注意!肝素污染时PT可能正常!

及时识别出因为药物干扰而导致的异常结果,避免将错误的结果发往临床,这对实验室人员提出了挑战。本文分享一起近期遇到的低剂量肝素导致部分血凝指标异常的案例